UNSPSC 51332201: Berupipam

This classification denotes a dopamine antagonist with the molecular formula C19H19BrClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 420895MAOC, chemically known as (+)-(5s)-5-(5-bromo-2,3-dihydro-7-benzofuranyl)-8-chloro-2,3,4,5-tetrahydro-3-methyl-1h-3-benzazepin-7-ol but generally known as berupipam, which bears US NIH Compound Identifier 66002. European Medicines Agency schedules Berupipam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05784MIG.

UNSPSC 51332201 Berupipam (Commodity) does not map to the work actually being solicited under this code in recent state and local opportunities. The three recent opportunities tagged with this code—naloxone and drug deactivation systems procurement from Seminole County, Florida; a Texas HHS Commission request for information on direct-to-manufacturer prescription programs; and a Minnesota cooperative purchasing alliance RFP for generic multi-source pharmaceuticals and OTC products—involve pharmaceutical procurement, supply-chain management, and pharmacy benefit administration, none of which align with berupipam as a pharmaceutical product or service line. The code's recent activity shows a mix of issuing bodies including county health departments (Seminole County), state health and human services agencies (Texas HHS Commission), and cooperative purchasing consortiums serving multiple state jurisdictions (Minnesota MMCAP, which includes Oregon), but the sourcing activity reflects broader pharmacy and medication procurement rather than a discrete commodity category.

Geographic activity spans Florida, Texas, and Minnesota, with cooperative purchasing mechanisms extending coverage to additional states including Oregon. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a due date of July 26, 2023; Texas HHS Commission's RFI for direct-to-manufacturer prescription program capabilities with a response deadline of April 3, 2026; and Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products with a proposal deadline of March 26, 2026, requiring vendors to supply through authorized wholesalers and maintain cGMP and Drug Supply Chain Security Act compliance. The code exhibits minimal recent procurement activity directly aligned with berupipam itself; business development professionals should verify code assignment before pursuing opportunities tagged under this commodity.